Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: An immunohistochemical study

Journal of Clinical Pathology

Volumn 64, Issue 11, 2011, Pages 977-982

  Kharaishvili, Gvantsa ^a   Cizkova, Magdalena ^a   Bouchalova, Katerina ^a   Mgebrishvili, Giorgi ^a   Kolar, Zdenek ^a   Bouchal, Jan ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SCLEROPROTEIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VERSICAN; WNT PROTEIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; METASTASIS; OSSIFICATION; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; VERSICANS;

EID: 80054962098     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200106     Document Type: Article

References (37)

1. Tang L, Dai DL, Su M, et al. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 2006;12:3716-22. (Pubitemid 44000252)
2. Turashvili G, Bouchal J, Baumforth K, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007;7:55.
3. Pyagay P, Heroult M, Wang Q, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 2005;96:261-8. (Pubitemid 40209374)
4. Durmus T, LeClair RJ, Park KS, et al. Expression analysis of the novel gene collagen triple helix repeat containing-1 (Cthrc1). Gene Expr Patterns 2006;6:935-40. (Pubitemid 44309445)
5. LeClair R, Lindner V. The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor beta signaling. Trends Cardiovasc Med 2007;17:202-5. (Pubitemid 47089010)
6. Yamamoto S, Nishimura O, Misaki K, et al. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell 2008;15:23-36. (Pubitemid 351895602)
7. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 2009;66:2219-30.
8. Puglisi F, Puppin C, Pegolo E, et al. Expression of periostin in human breast cancer. J Clin Pathol 2008;61:494-8. (Pubitemid 351518233)
9. Hong L, Sun H, Lv X, et al. Expression of periostin in the serum of NSCLC and its function on proliferation and migration of human lung adenocarcinoma cell line (A549) in vitro. Mol Biol Rep 2010;37:2285-93.
10. Streit S, Michalski CW, Erkan M, et al. Confirmation of DNA microarray-derived differentially expressed genes in pancreatic cancer using quantitative RT-PCR. Pancreatology 2009;9:577-82.
11. Michaylira CZ, Wong GS, Miller CG, et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res 2010;70:5281-92.
12. Sutton CW, Rustogi N, Gurkan C, et al. Quantitative proteomic profiling of matched normal and tumor breast tissues. J Proteome Res 2010;9:3891-902.
13. Tischler V, Fritzsche FR, Wild PJ, et al. Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer 2010;10:273.
14. Zhu M, Fejzo MS, Anderson L, et al. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol 2010;119:337-44.
15. Contie S, Voorzanger-Rousselot N, Litvin J, et al. Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer 2011;128:352-60.
16. Sasaki H, Yu CY, Dai M, et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 2003;77:245-52. (Pubitemid 36197639)
17. Rahmani M, Wong BW, Ang L, et al. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 2006;84:77-92. (Pubitemid 44011953)
18. Zheng PS, Wen J, Ang LC, et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 2004;18:754-6.
19. Nikitovic D, Zafiropoulos A, Katonis P, et al. Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 2006;58:47-53.
20. Wight TN. Arterial remodeling in vascular disease: a key role for hyaluronan and versican. Front Biosci 2008;13:4933-7. (Pubitemid 351599647)
21. Nara Y, Kato Y, Torii Y, et al. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/ versican. Histochem J 1997;29:21-30. (Pubitemid 27173645)
22. Touab M, Villena J, Barranco C, et al. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002;160:549-57.
23. Miquel-Serra L, Serra M, Hernandez D, et al. V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Lab Invest 2006;86:889-901. (Pubitemid 44268164)
24. Kischel P, Waltregny D, Dumont B, et al. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 2010;26:640-50.
25. West RB, Nuyten DS, Subramanian S, et al. Determination of stromal signatures in breast carcinoma. PLoS Biol 2005;3:e187.
26. Tano K, Mizuno R, Okada T, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett 2010;584:4575-80.
27. Wang L, Xiang YN, Zhang YH, et al. Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma. Br J Dermatol 2010;164:135-40.
28. Soikkeli J, Podlasz P, Yin M, et al. Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol 2010;177:387-403.
29. Yan W, Shao R. Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem 2006;281:19700-8.
30. Shao R, Bao S, Bai X, et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 2004;24:3992-4003. (Pubitemid 38496176)
31. Grigoriadis A, Mackay A, Reis-Filho JS, et al. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res 2006;8:R56.
32. Smirnov DA, Foulk BW, Doyle GV, et al. Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res 2006;66:2918-22.
33. Barginear M, Clotfelter A, Poznak CV. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer. Clin Breast Cancer 2009;9:72-6.
34. Theriault R. Bone-directed therapy and breast cancer: Bisphosphonates, Monoclonal Antibody, and Radionuclides. In: Harris J, Lippman ME, Osborne CK, et al., eds. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2010.
35. Kimura H, Kwan KM, Zhang Z, et al. Cthrc1 is a positive regulator of osteoblastic bone formation. PLoS One 2008;3:e3174.
36. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
37. Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009;115:423-8.